王莉;赵志亮;刘芳;罗永;王姣乐;巩伟兵;尹海萍;梁钰;宋晓芸;高云新;张妙婷;

• 1:甘肃国际旅行卫生保健中心兰州海关口岸门诊部

摘要(Abstract)：

新型冠状病毒（SARS-CoV-2）作为一种单链RNA病毒，可引起人类严重的呼吸道综合征。本研究对2020年3月至2021年1月甘肃口岸入境人员中经RT-PCR检测SARS-CoV-2核酸阳性的8份样本进行全基因组测序，并用MEGA11软件以邻接法构建系统发育树，以揭示甘肃口岸输入性SARS-CoV-2基因组特征和遗传进化关系。全基因组测序获得8条长度为29 252bp～29 833bp的SARS-CoV-2基因组序列，基因组覆盖度97.82%～99.77%。与武汉参考株（GISAID号：EPI＿ISL＿402119）相比，共检测到64个错义突变，31个同义突变，3个移码突变和5个非编码等位基因。按照Pangolin分型法，8株输入性毒株属于B.1和B.4谱系。系统发育树分析显示来自伊朗的2例毒株聚集于同一进化支，其他6例毒株分布于不同的进化支中，与目前全球流行的关注变异株和武汉参考株均位于不同进化分支。值得注意的是，一株2020年10月份从俄罗斯输入的B.1.1.523谱系毒株出现时间早于文献报道的2021年3月份，说明该谱系可能在2020年10月或更早就已在俄罗斯流行。

关键词(KeyWords)： 新型冠状病毒;全基因组测序;基因组特征

Abstract:

Keywords:

基金项目(Foundation): 海关总署科研项目计划（项目号：2020HK131）,题目：口岸输入性新型冠状病毒核酸精准检测技术及分子溯源研究~~

作者(Authors): 王莉;赵志亮;刘芳;罗永;王姣乐;巩伟兵;尹海萍;梁钰;宋晓芸;高云新;张妙婷;

DOI: 10.13242/j.cnki.bingduxuebao.004253

参考文献(References)：

• [1] Wu F,Zhao S,Yu B,Chen Y M,Wang W,Song Z G,Hu Y,Tao Z W,Tian J H,Pei Y Y,Yuan M L,Zhang Y L,Dai F H,Liu Y,Wang Q M,Zheng J J,Xu L,Holmes E C,Zhang Y Z. A new coronavirus associated with human respiratory disease in China[J]. Nature,2020,579(7798):265-269.
• [2] Chan J F,Kok K H,Zhu Z,Chu H,To K K,Yuan S,Yuen K Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J].Emerg Microbes Infect, 2020,9(1):221-236.
• [3] Organization WHO.2020.Coronavirus disease(COVID-19)pandemic.Accessed 2 Jul,2020.
• [4] Li R,Pei S,Chen B,Song Y,Zhang T,Yang W,Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus(SARSCoV-2)[J].Science,2020,368(6490):489-493.
• [5] Jeon S,Ko M,Lee J,Choi I,Byun S Y,Park S,Shum D,Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs[J/OL]. Antimicrob Agents Chemother,2020,64(7):e00819-20.
• [6]宋洋，许文波.新型冠状病毒基因组序列的网络平台与基因分型[J/OL].病毒学报，2021,37(1):1-10. DOI:10.13242/j.cnki.bingduxuebao.003837
• [7] Emma B Hodcroft,James Hadfield,Richard A Neher,Bedford T.Year-letter genetic clade naming for SARSCoV-2 on nextstain.Org[EB/OL].June 2,2020.
• [8] Rambaut A,Holmes EC,O'Tooleá，Hill V,McCrone JT,Ruis C,du Plessis L,Pybus OG. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology[J].Nat Microbiol.2020,5(11):1403-1407.
• [9] Salehi N,Amiri-Yekta A,Totonchi M.Profiling of initial available SARS-CoV-2 sequences from Iranian related COVID-19 patients[J].Cell J,2020,22(Suppl 1):148-150.
• [10]Gong Y N,Tsao K C,Hsiao M J,Huang C G,Huang P N,Huang P W,Lee K M,Liu Y C,Yang S L,Kuo R L,Chen K F,Liu Y C,Huang S Y,Huang H I,Liu M T,Yang J R,Chiu C H,Yang C T,Chen G W,Shih S R.SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East[J]. Emerg Microbes Infect,2020,9(1):1457-1466.
• [11]Potdar V,Cherian S S,Deshpande G R,Ullas P T,Yadav P D,Choudhary M L,Gughe R,Vipat V,Jadhav S,Patil S,Nyayanit D,Majumdar T,Walimbe A,Gaikwad S,Dighe H,Shete-Aich A,Mohandas S,Chowdhury D, Sapkal G, Basu A, Gupta N,Gangakhedkar RR,Giri S,Dar L,Jain A,Malhotra B,Abraham P;National Influenza Centre(NIC)Team:.Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy,Iran&China,&Italian tourists in India[J]. Indian J Med Res,2020,151(2&3):255-260.
• [12]Fattahi Z, Mohseni M, Jalalvand K, Aghakhani Moghadam F,Ghaziasadi A,Keshavarzi F,Yavarian J,Jafarpour A,Mortazavi S E,Ghodratpour F,Behravan H,Khazeni M,Momeni S A,Jahanzad I,Moradi A,Tabarraei A,Azimi SA,Kord E,Hashemi-Shahri SM,Azaran A,Yousefi F,Mokhames Z,Soleimani A,Ghafari S,Ziaee M,Habibzadeh S,Jeddi F,Hadadi A,Abdollahi A,Kaydani G A,Soltani S,Mokhtari-Azad T,Najafipour R,Malekzadeh R,Kahrizi K,Jazayeri SM,Najmabadi H. SARS-CoV-2 outbreak in Iran:The dynamics of the epidemic and evidence on two independent introductions[J]. Transbound Emerg Dis,2021,1111/tbed.14104.
• [13]Eden J S,Rockett R,Carter I,Rahman H,de Ligt J,Hadfield J,Storey M,Ren X,Tulloch R,Basile K,Wells J,Byun R,Gilroy N,O'Sullivan M V,Sintchenko V,Chen S C,Maddocks S,Sorrell T C,Holmes E C,Dwyer D E,Kok J;2019-nCoV study group. An emergent clade of SARS-CoV-2 linked to returned travellers from Iran[J].Virus Evol,2020,6(1):veaa027.
• [14]Feghali R,Merhi G,Kwasiborski A,Hourdel V,Ghosn N, Tokajian S. Genomic characterization and phylogenetic analysis of the first SARS-CoV-2 variants introduced in Lebanon[J/OL].Peer J.2021,9:e11015.
• [15]Koyama T,Platt D,Parida L.Variant analysis of SARSCoV-2 genomes[J].Bull World Health Organ, 2020,98(7):495-504.
• [16]Yin C.Genotyping coronavirus SARS-CoV-2:methods and implications[J]. Genomics,2020,112(5):3588-3596.
• [17]Korber B,Fischer W M,Gnanakaran S,Yoon H,Theiler J,Abfalterer W,Hengartner N,Giorgi E E,Bhattacharya T,Foley B,Hastie K M,Parker M D,Partridge D G,Evans C M,Freeman T M,de Silva T I;Sheffield COVID-19 Genomics Group,McDanal C,Perez L G,Tang H,Moon-Walker A,Whelan S P,LaBranche C C,Saphire E O,Montefiori D C.Tracking changes in SARS-CoV-2 spike:evidence that D614G increases infectivity of the COVID-19 virus[J].Cell,2020,182(4):812-827.
• [18]Volz E,Hill V,McCrone J T,Price A,Jorgensen D,O'Tooleá，Southgate J,Johnson R,Jackson B,Nascimento F F,Rey S M,Nicholls S M,Colquhoun R M,da Silva Filipe A,Shepherd J,Pascall D J,Shah R,Jesudason N,Li K,Jarrett R,Pacchiarini N,Bull M,Geidelberg L,Siveroni I;COG-UK Consortium,Goodfellow I,Loman N J,Pybus O G,Robertson D L,Thomson E C,Rambaut A,Connor TR. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity[J].Cell,2021,184(1):64-75.
• [19]Zhang L,Jackson C B,Mou H,Ojha A,Rangarajan E S,Izard T,Farzan M,Choe H.The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity[J].bioRxiv,2020.06.12.148726.
• [20]Zhao S,Lou J,Cao L,Zheng H,Chong M.K.C,Chen Z,Chan R. W. Y,Zee B. C. Y,Chan P. K. S,Wang M. H.Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the United Kingdom:An early data-driven analysis[J]. J. Travel Med,2021,28:taab011.
• [21]Hoffmann M,Arora P,Gro?R,Seidel A,H?rnich B.F,Hahn A.S,Krüger N,Graichen L,Hofmann-Winkler H,Kempf A,et al.SARS-CoV-2 variants B.1.351 and P.1escape from neutralizing antibodies[J/OL]. Cell,2021,184:2384–2393.e12.
• [22]Aria C.Shi,Xuping Xie.Making sense of spike D614G in SARS-CoV-2 transmission[J]. Science China(Life Sciences),2021,64(07):1062-1067.
• [23]C Caserta L, Mitchell P K, Plocharczyk E, Diel D G.Identification of a SARS-CoV-2 lineage B1.1.7 virus in New York following return travel from the United Kingdom[J/OL]. Microbiol Resour Announc,2021,10:e00097-e21.
• [24]Wu H,Xing N,Meng K,Fu B,Xue W,Dong P,Tang W,Xiao Y,Liu G,Luo H,Zhu W,Lin X,Meng G,Zhu Z. Nucleocapsid mutations R203K/G204R increase the infectivity,fitness,and virulence of SARS-CoV-2[J/OL].Cell Host Microbe,2021,29(12):1788-1801.e6.
• [25]Leary S, Gaudieri S, Parker MD, Chopra A, James I,Pakala S, Alves E, John M, Lindsey BB, Keeley AJ,Rowland-Jones SL, Swanson MS, Ostrov DA,Bubenik JL, Das SR, Sidney J, Sette A; COVID-19Genomics UK(COG-UK)consortium, de Silva TI,Phillips E, Mallal S. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid:homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level[J/OL]. Pathog Immun, 2021,6(2):27-49.
• [26]Candido D S,Claro I M,de Jesus J G,Souza W M,Moreira F R R,Dellicour S,Mellan T A,du Plessis L,Pereira R H M,Sales F C S,Manuli E R,ThézéJ,Almeida L,Menezes M T,Voloch C M,Fumagalli M J,Coletti T M,da Silva C A M,Ramundo M S,Amorim M R,Hoeltgebaum H H,Mishra S,Gill M S,Carvalho L M,Buss L F,Prete C A,Ashworth J,Nakaya H I,Peixoto P S,Brady O J,Nicholls S M,Tanuri A,RossiáD,Braga C K V,Gerber A L,de C Guimar?es A P,Gaburo N,Alencar C S,Ferreira ACS,Lima CX,Levi JE,Granato C,Ferreira G M,Francisco R S,Granja F,Garcia M T,Moretti M L,Perroud M W,Casti?eiras T M P P,Lazari C S,Hill S C,de Souza Santos A A,Simeoni C L,Forato J,Sposito A C,Schreiber A Z,Santos M N N,de SáC Z,Souza R P,Resende-Moreira L C,Teixeira M M,Hubner J,Leme P A F,Moreira R G,Nogueira M L;Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology(CADDE)Genomic Network,Ferguson NM,Costa S F,Proenca-Modena J L,Vasconcelos A T R,Bhatt S,Lemey P,Wu C H,Rambaut A,Loman N J,Aguiar R S,Pybus O G,Sabino E C,Faria N R. Evolution and epidemic spread of SARS-CoV-2 in Brazil[J].Science,2020,369(6508):1255-1260.
• [27]Lukas Zemaitis,Gediminas Alzbutas,Dovydas Gecys,Andrey Komissarov, Arnoldas Pautienius, Rasa Ugenskiene, Marius Sukys, Vaiva Lesauskaite.Determining international spread of novel B. 1.1.523SARS-CoV-2 lineage[J].medRxiv,2021.
• [28]Brian M.J. W. van der Veer,Jozef Dingemans,Lieke B.van Alphen,Christian J. P. A. Hoebe,Paul H. M.Savelkoul.A novel B.1.1.523 SARS-CoV-2 variant that combines many spike mutations linked to immune evasion with current variants of concern[J]. bioRxiv,2021.
• [29]Greaney A J,Loes A N,Crawford K H D,Starr T N,Malone K D,Chu H Y,Bloom J D. Comprehensive mapping of mutations in the SARS-CoV-2 receptorbinding domain that affect recognition by polyclonal human plasma antibodies[J/OL]. Cell Host Microbe,2021,29(3):463-476.e6.
• [30]Collier D A,De Marco A,Ferreira I A T M,Meng B,Datir R P,Walls A C,Kemp S A,Bassi J,Pinto D,Silacci-Fregni C,Bianchi S,Tortorici M A,Bowen J,Culap K,Jaconi S,Cameroni E,Snell G,Pizzuto M S,Pellanda A F,Garzoni C,Riva A;CITIID-NIHR BioResource COVID-19 Collaboration,Elmer A,Kingston N,Graves B,McCoy L E,Smith K G C,Bradley J R,Temperton N,Ceron-Gutierrez L,BarcenasMorales G;COVID-19 Genomics UK(COG-UK)Consortium,Harvey W,Virgin H W,Lanzavecchia A,Piccoli L,Doffinger R,Wills M,Veesler D,Corti D,Gupta R K. Sensitivity of SARS-CoV-2 B. 1.1.7 to mRNA vaccine-elicited antibodies[J].Nature,2021,593(7857):136-141.
• [31]Erica Lasek-Nesselquist, Janice Pata, Erasmus Schneider,Kirsten St. George. A tale of three SARSCoV-2 variants with independently acquired P681H mutations in New York State[J].medRxiv,2021.